ARCT: Arcturus Therapeutics Holdings, Inc.
About
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Current Value
$17.941 Year Return
Current Value
$17.941 Year Return
Key Details
Market Cap
$489.20M
P/E Ratio
-8.16
1Y Stock Return
-21.27%
1Y Revenue Growth
-50.30%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include ARCT
Stock's related to ARCT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ABCL | 48.74% | $800.44M | -37.56% | 0.00% |
| CRSP | 46.89% | $4.01B | -30.49% | 0.00% |
| BEAM | 46.57% | $2.09B | -9.52% | 0.00% |
| TWST | 43.18% | $2.42B | +74.27% | 0.00% |
| PGEN | 43.07% | $228.91M | -28.00% | 0.00% |
| AGIO | 43.03% | $3.10B | +148.79% | 0.00% |
| RXRX | 42.60% | $1.80B | -4.13% | 0.00% |
| DMRC | 41.83% | $694.39M | -2.06% | 0.00% |
| INSM | 41.66% | $13.19B | +202.50% | 0.00% |
| SPCE | 41.20% | $196.64M | -84.01% | 0.00% |
| ADPT | 41.17% | $661.15M | +6.16% | 0.00% |
| VIR | 40.39% | $954.40M | -26.51% | 0.00% |
| ALEC | 39.07% | $377.04M | -19.46% | 0.00% |
| PLRX | 38.92% | $778.32M | -9.55% | 0.00% |
| NG | 38.29% | $1.22B | -5.91% | 0.00% |
| KRYS | 38.16% | $5.12B | +75.65% | 0.00% |
| CDXS | 38.07% | $345.86M | +121.35% | 0.00% |
| ALLO | 37.87% | $444.50M | -24.82% | 0.00% |
| GPRO | 37.83% | $179.52M | -67.23% | 0.00% |
| ADTN | 37.58% | $627.65M | +47.76% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KDP | -0.02% | $42.76B | -1.22% | 2.77% |
| GD | -0.06% | $77.26B | +14.02% | 1.98% |
| DXCM | 0.10% | $29.25B | -31.28% | 0.00% |
| LITB | 0.17% | $35.48M | -75.45% | 0.00% |
| FENG | -0.21% | $13.37M | +96.77% | 0.00% |
| AGX | 0.23% | $2.01B | +224.91% | 0.85% |
| LPLA | 0.24% | $23.55B | +38.13% | 0.38% |
| ERIE | -0.25% | $19.39B | +46.23% | 1.23% |
| RILY | 0.25% | $145.72M | -79.86% | 20.75% |
| CAG | -0.26% | $12.64B | -6.10% | 5.26% |
| TTE | 0.27% | $138.45B | -11.95% | 5.50% |
| FATBB | -0.42% | $81.94M | -12.91% | 11.69% |
| MKC | -0.43% | $20.21B | +15.19% | 2.23% |
| TPB | -0.46% | $1.08B | +167.44% | 0.45% |
| AMED | 0.53% | $2.95B | -3.95% | 0.00% |
| BK | 0.57% | $56.43B | +65.37% | 2.29% |
| CLX | 0.60% | $20.81B | +20.66% | 2.88% |
| BSX | 0.74% | $133.13B | +63.29% | 0.00% |
| AWH | 0.76% | $11.44M | -76.87% | 0.00% |
| CMG | 0.76% | $80.02B | +33.62% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGR | -16.39% | $149.10B | +57.29% | 0.45% |
| PULM | -13.78% | $19.83M | +202.98% | 0.00% |
| MMC | -13.43% | $108.41B | +10.89% | 1.37% |
| RSG | -12.70% | $66.05B | +31.79% | 1.04% |
| STG | -12.59% | $35.67M | +7.92% | 0.00% |
| MCK | -11.23% | $78.15B | +35.51% | 0.42% |
| LMT | -11.12% | $126.40B | +18.99% | 2.36% |
| GIS | -11.10% | $34.85B | -2.91% | 3.78% |
| CBOE | -11.10% | $21.46B | +15.84% | 1.11% |
| PEP | -10.09% | $215.02B | -6.60% | 3.35% |
| CHKP | -9.73% | $19.20B | +20.74% | 0.00% |
| TCTM | -9.71% | $8.10M | -42.99% | 0.00% |
| AJG | -9.68% | $64.17B | +17.51% | 0.80% |
| K | -9.67% | $27.77B | +52.50% | 2.79% |
| CPB | -9.31% | $12.96B | +7.08% | 3.40% |
| CL | -9.30% | $76.48B | +22.25% | 2.12% |
| COR | -8.73% | $47.48B | +21.20% | 0.86% |
| CME | -8.52% | $82.76B | +9.21% | 1.98% |
| CHD | -8.48% | $27.18B | +19.50% | 1.03% |
| ACGL | -8.41% | $36.00B | +16.84% | 0.00% |
ETF's related to ARCT
News
Yahoo
SAN DIEGO, November 19, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.
SeekingAlpha
Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.
Yahoo
TOKYO, November 14, 2024--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS").
Yahoo
SAN DIEGO, November 11, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a "Study Can Proceed" notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine c
Yahoo
Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Third Quarter 2024 Results Key Financial Results Revenue: US$41.7m (down...
Yahoo
Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.